Media/Policy Watch

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
 
 
Financial Times
http://www.ft.com/home/uk
Biotech
Secretive Moderna yet to convince on $5bn valuation
Biotech hopes to turn our bodies into ‘drug factories’ able to create own cure
September 6, 2017
 
Middle East & North Africa
Yemenis fight for survival in country on the brink of famine
Millions of lives at risk as civil war leads to cholera epidemic and food shortages
September 8, 2017
 
Forbes
http://www.forbes.com/
Accessed 9 September 2017
Personalized Cancer Vaccine Company Raises $93 Million
Matthew Herper, Forbes Staff
Venture funds seeded by drug giant Eli Lilly and search behemoth Alphabet are giving $92.7 million to a startup that aims to use machine learning to create personalized treatments for lung and stomach cancer… Gritstone Oncology, based in Emeryville, Calif., will use the money to build a 43,000-square-foot manufacturing facility for its treatments, and to fund clinical trials in human beings, which have not begun yet and are expected to start in the middle of next year.     Gritstone had previously raised $103 million; Andrew Allen, its chief executive, says that about $15 million of those funds remained. The new funds will take Gritstone through its first clinical trial results, expected at the end of 2019, Allen says…

 
New Yorker
http://www.newyorker.com/
Accessed 9 September 2017
Elements
Is Zika Gone for Good?
The virus caused widespread illness and fear in 2016, but it has virtually disappeared from the continental United States. Why?
By Jerome Groopman
September 2, 2017

New York Times
http://www.nytimes.com/
Accessed 9 September 2017
For Meningitis B Vaccines, Climbing Revenue, and Plenty of Skepticism
Two drug firms have developed pricey vaccines they are advertising widely on TV, raising concerns among experts that they are stoking parents’ fears about a rare disease unnecessarily.
September 07, 2017 – By SHEFALI LUTHRA
 
Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 9 September 2017
Business
Sanofi Stops Work on Two Zika Vaccines
By Peter Loftus
Sep. 6, 2017 5:41 pm ET
Drugmaker Sanofi has ended its development of two Zika virus vaccines, citing a decline in new infections and limits on U.S. government funding.